CFA FRM - Belite Bio CFO Director
| BLTE Stock | USD 64.00 0.74 1.17% |
Insider
CFA FRM is CFO Director of Belite Bio ADR
| Age | 38 |
| Address | 12750 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 246 6240 |
| Web | https://www.belitebio.com |
Belite Bio Management Efficiency
The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4004) %, meaning that it created substantial loss on money invested by shareholders. Belite Bio's management efficiency ratios could be used to measure how well Belite Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.37. At present, Belite Bio's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.04, whereas Net Tangible Assets are forecasted to decline to (14.3 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Donna Dea | Aerovate Therapeutics | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Eric Lindquist | Celcuity LLC | N/A | |
| Lance Laing | Celcuity LLC | 62 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Jc MD | Adagene | 59 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| MBA BS | AN2 Therapeutics | 49 | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Hakon Leffler | Galecto | N/A | |
| MBA MBA | Immuneering Corp | 39 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Filip MD | Monte Rosa Therapeutics | 50 | |
| Sarah Carmody | Vigil Neuroscience | N/A | |
| Timothy Pigot | Aerovate Therapeutics | 53 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
Management Performance
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.26 |
Belite Bio ADR Leadership Team
Elected by the shareholders, the Belite Bio's board of directors comprises two types of representatives: Belite Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Belite. The board's role is to monitor Belite Bio's management team and ensure that shareholders' interests are well served. Belite Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Belite Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChingChen MSc, VP Operations | ||
| YuHsin MBA, Chairman CEO | ||
| CFA FRM, CFO Director | ||
| MA MD, Chief Board | ||
| Nathan Mata, Chief Officer |
Belite Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Belite Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 1.87 B | ||||
| Shares Outstanding | 30.88 M | ||||
| Shares Owned By Insiders | 58.60 % | ||||
| Shares Owned By Institutions | 0.49 % | ||||
| Number Of Shares Shorted | 241.07 K | ||||
| Price To Book | 17.41 X | ||||
| EBITDA | (31.53 M) | ||||
| Net Income | (31.63 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Belite Bio ADR is a strong investment it is important to analyze Belite Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Belite Bio's future performance. For an informed investment choice regarding Belite Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Belite Bio ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Belite Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.